HCWB 3.50... a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today the latest updated data for its tetra-valent, second-generation pembrolizumab-based Immune Checkpoint Inhibitor (“ICI”) Program constructed using the Company’s novel TRBC platform, presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC2025”) which took place from November 5 to 9, 2025 in National Harbor, MD.The Company’s lead product candidate in its ICI program, HCW11-040, is a novel multi-functional fusion protein molecule, constructed with a unique combination IL-15 and IL-7 domains and a Transforming Growth Factor ß (“TGF-ß”) trap. It demonstrates PD-1/PD-L1 blocking activity equivalent to pembrolizumab (generic form of Keytruda®) in preclinical studies. Results of these preclinical studies also highlight the advantages of HCW11-040 over the first generation immune checkpoint inhibitors:Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, “The preclinical data we shared at SITC2025 showed the details related to our discovery and selection of HCW11-040 as our franchise-building molecule for cancer and other age-related diseases. Our data shows that we verified the ability of HCW11-040 to expand and activate TPEX cells and promote anti-tumor activity of human peripheral blood mononuclear cells against human cancer cells without triggering cytokine storm side effects. Based on these encouraging results, we will vigorously advance additional IND-enabling studies for HCW11-040, including the creation of a high-expression manufacturing cell bank, manufacturing process development, and preclinical Good Laboratory Practice toxicology studies.”KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the company is not affiliated with HCWB.
Market Data 
Markets 
AI
